These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 21864888

  • 21. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW.
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 24. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF, Pizer ES, Ronnett BM, Kurman RJ.
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [Abstract] [Full Text] [Related]

  • 25. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D.
    Eur J Gynaecol Oncol; 2001 Jun; 22(2):122-6. PubMed ID: 11446475
    [Abstract] [Full Text] [Related]

  • 26. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, Soslow RA.
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [Abstract] [Full Text] [Related]

  • 27. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
    Koyuncuoglu M, Okyay E, Saatli B, Olgan S, Akin M, Saygili U.
    Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
    [Abstract] [Full Text] [Related]

  • 28. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW.
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [Abstract] [Full Text] [Related]

  • 29. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
    Cirisano FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL.
    Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
    [Abstract] [Full Text] [Related]

  • 30. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
    Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG.
    Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
    [Abstract] [Full Text] [Related]

  • 31. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF, Liu MQ, Zhao Q.
    Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
    [Abstract] [Full Text] [Related]

  • 32. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Miyazaki K.
    Oncology; 2013 Sep; 84(3):166-73. PubMed ID: 23306391
    [Abstract] [Full Text] [Related]

  • 33. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X, Dong Y, Zhang XM, Liang Y, Zhang Y, Meng YT, Wang Y, Wang W, Nong L, Li T, Liao QP.
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.